Intellia launches $150 mln stock offering following gene therapy trial; shares drop

Jefferies Financial

27/04/2026 21:32

** Shares of biopharma firm Intellia Therapeutics NTLA.O down 2.5% post-market to $12.72 as it looks to raise equity following late-stage trial results

** NTLA shares finished down 4.3% at $13.04 on Mon after co said its experimental gene-editing therapy reduced the frequency of swelling attacks in patients with a rare genetic disorder in a late-stage trial

** Results prompt co to start a rolling submission of its data for the gene therapy as it aims for the U.S. Food and Drug Administration's approval next year, NTLA said

** After the bell, co commences $150 mln stock offering

** Jefferies, Goldman Sachs and Citigroup joint bookrunners

** Cambridge, Massachusetts-based NTLA has ~118.1 mln shares outstanding for about $1.5 bln market cap

    ** At Mon close, stock up 45% YTD

    ** Avg rating of 24 analysts is "buy"; median PT $16, per LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))